

1 Full Title:

2 **Tumor Necrosis Factor (TNF) Blocking Agents Reduce Risk for Alzheimer’s Disease in Patients with**  
3 **Rheumatoid Arthritis and Psoriasis**

4

5 Short Title:

6 TNF Blocking Agents Reduce Risk for Alzheimer’s Disease in Patients with Rheumatoid Arthritis and Psoriasis

7

8 Authors:

9 Mengshi Zhou<sup>1</sup>, Rong Xu<sup>1</sup>, David C. Kaelber<sup>1,2</sup>, and Mark E. Gurney<sup>3</sup>

10 <sup>1</sup>Department of Population and Quantitative Health Sciences, School of Medicine, Case Western Reserve  
11 University, Cleveland, OH44106

12 <sup>2</sup>Departments of Internal Medicine and Pediatrics and the Center for Clinical Informatics Research and Education,  
13 The MetroHealth System, Cleveland, OH, USA

14 <sup>3</sup>Tetra Therapeutics, 38 Fulton Street West, Grand Rapids, MI 49503

15

16 Corresponding Authors:

17 Rong Xu

18 Email: rxx@case.edu

19 Mark Gurney

20 Email: mark@tetratherapeutics.com

21

22 **Abstract**

23 This large, retrospective case-control study of electronic health records from 56 million unique adult patients  
24 examined whether or not treatment with a Tumor Necrosis Factor (TNF) blocking agent reduced risk for  
25 Alzheimer's disease (AD) in patients with rheumatoid arthritis (RA), psoriasis, and other inflammatory diseases  
26 which are mediated in part by TNF and for which a TNF blocker is an approved treatment. The analysis  
27 compared the diagnosis of AD as an outcome measure in patients receiving at least one prescription for a TNF  
28 blocking agent (etanercept, adalimumab, and infliximab) or for methotrexate. RA increased the risk for AD  
29 (Adjusted Odds Ratio (AOR) = 2.06, 95% Confidence Interval: (2.02-2.10),  $P$ -value <0.0001) as did psoriasis  
30 (AOR = 1.37 (1.31-1.42),  $P$  <0.0001), ankylosing spondylitis (AOR = 1.57 (1.39-1.77),  $P$  <0.0001),  
31 inflammatory bowel disease (AOR = 2.46 (2.33-2.59),  $P$  < 0.0001), ulcerative colitis (AOR = 1.82 (1.74-1.91),  $P$   
32 <0.0001), and Crohn's disease (AOR = 2.33 (2.22-2.43),  $P$  <0.0001). The risk for AD in patients with RA was  
33 reduced by treatment with etanercept (AOR = 0.34 (0.25-0.47),  $P$  <0.0001), adalimumab (AOR = 0.28 (0.19-  
34 0.39),  $P$  < 0.0001), and infliximab (AOR = 0.52 (0.39-0.69),  $P$  <0.0001). Methotrexate also reduced risk for  
35 Alzheimer's disease (AOR = 0.64 (0.61-0.68),  $P$  <0.0001), while further risk reduction was achieved in patients  
36 with a prescription history for both a TNF blocker and methotrexate. Etanercept and adalimumab also reduced  
37 the risk for AD in patients with psoriasis: AOR = 0.47 (0.30-0.73 and 0.41 (0.20-0.76), respectively. There was  
38 no effect of gender or race, while younger patients showed greater benefit from a TNF blocker than did older  
39 patients. This study identifies a subset of patients in whom systemic inflammation contributes to risk for AD  
40 through a pathological mechanism involving TNF and who therefore may benefit from treatment with a TNF  
41 blocking agent.

## 42 **Introduction**

43 Alzheimer's disease (AD) is the most common cause of dementia. Characteristic pathology in brain includes the  
44 presence of plaques (deposits of amyloid- $\beta$  peptide) and tangles (intraneuronal deposits of hyperphosphorylated  
45 tau protein) [1, 2]. These occur in hippocampus and associational cortex, regions of the brain important for  
46 cognitive function. Accumulation of amyloid plaque occurs over many years and generally precedes accumulation  
47 of intraneuronal tangles and cognitive dysfunction [2]. Progression of disease is associated with neuronal  
48 degeneration, cortical thinning, and deepening and severe cognitive impairment. Neuroinflammatory changes  
49 around the amyloid plaques include reactive astrocytosis and microglial cell activation [3]. Microglia cells, the  
50 resident macrophages in the brain, derive embryonically from the same myeloid stem cells in bone marrow that  
51 give rise to monocytes and macrophages elsewhere in the body [4]. Macrophages are one of the important drivers  
52 of systemic inflammation through the overproduction of tumor necrosis factor (TNF) and other proinflammatory  
53 cytokines [5]. In the brain, elevation of TNF in cerebrospinal fluid collected from subjects with mild cognitive  
54 impairment is associated with progression to Alzheimer's disease at 6 months follow up [6]. Multiple lines of  
55 evidence indicate that TNF may trigger or amplify aberrant microglia signaling in the brain [7-10] and thereby  
56 contribute to Alzheimer's disease pathogenesis.

57 Multiple systemic inflammatory diseases are caused in part by the production of TNF by activated macrophages  
58 and these can be treated effectively with a TNF blocking agent. Approved indications for TNF blockers include  
59 rheumatoid arthritis (RA), ankylosing spondylitis, psoriasis, psoriatic arthritis, ulcerative colitis (UC) and Crohn's  
60 disease (CD) which are subtypes of inflammatory bowel disease (IBD) [5]. Inflammation in RA is localized to  
61 the synovial lining of the joints where synovial cell proliferation leads to a thickening of the lining, infiltration of  
62 activated macrophages and other inflammatory cells, elevated production of TNF, and irreversible destruction of  
63 the joint architecture and function [11]. TNF produced systemically may directly enter the brain through receptor-  
64 mediated transcytosis [12]. In mice, both types of TNF receptors, TNFR1 and TNFR2, participate in the transport  
65 of TNF across the blood brain barrier while other proteins present in blood are excluded. Thus, systemic  
66 production of TNF may directly affect inflammatory processes in the brain relevant to Alzheimer's disease.

67 We therefore sought to test the hypothesis that systemic inflammation involving TNF is associated with increased  
68 risk for Alzheimer's disease and that this could be mitigated by a TNF blocking agent. A previous case-control  
69 study of 8.5 million insured adults in the United States (US) reported increased risk for Alzheimer's disease in  
70 patients with RA and that etanercept, a TNF blocking agent prescribed for the treatment of RA, was associated  
71 with reduction of risk for AD (Adjusted Odds Ratio (AOR) = 0.30; 95% Confidence Interval (CI) = 0.08-0.87. *P*-  
72 value = 0.02) [13]. The study was based on 9,253 patients with Alzheimer's disease in the private insurance  
73 database.

74 Alzheimer's disease is underrepresented in US private insurance databases as most patients with Alzheimer's  
75 disease are older than 65, an age in the US when the majority of Americans transition from employer provided,  
76 private insurance to Medicare, a national health insurance program. We therefore undertook a retrospective study  
77 using the IBM Watson Healthcare Explorys Cohort Discovery platform which contains electronic health records  
78 (EHR) from patients with private insurance, Medicare and Medicaid. The Explorys Cohort Discovery platform  
79 contains the de-identified EHR of nearly 56 million unique patients with age  $\geq 18$  years from 26 healthcare  
80 systems across all 50 states in the US from 1999 to 2018. We expanded our analysis to other inflammatory  
81 diseases and to additional drugs in the class of TNF blocking agents to assess their potential effect on risk for  
82 Alzheimer's disease. Recent studies have shown that with this unique EHR database and built-in informatics  
83 tools, large hypothesis-driven case-control studies can be undertaken [14-16]. Sufficient patient EHR were  
84 available for the evaluation of co-morbid AD in patients with RA or psoriasis that were treated with etanercept,  
85 adalimumab, and infliximab. Etanercept (Enbrel®) is a fusion of soluble TNF receptor 2 with the Fc portion of  
86 mouse immunoglobulin G1 [17]. Adalimumab (Humira®) is a fully human, anti-TNF monoclonal antibody [18],  
87 while infliximab (Remicade®) is a chimeric mouse-human monoclonal antibody in which the antigen combining  
88 region of a mouse anti-TNF monoclonal antibody was fused to a human Fc domain [19]. Such large, biologic  
89 drugs are not expected to have good access to brain after subcutaneous or intravenous injection due to exclusion  
90 of protein macromolecules by the blood brain barrier [12, 20].

91

## 92 **Methods**

### 93 **Database description**

94 We performed a retrospective case-control study using de-identified population-level EHR collected by the IBM  
95 Watson Health Explorys Cohort Discovery platform from 360 hospitals and 317,000 providers [15]. The de-  
96 identified data are accessed using the Explore application from the Explorys Cohort Discovery platform. Explorys  
97 collects data from multiple health information system using a health data gateway (HGD) server. The data  
98 collected include patient demographics, disease diagnoses, medication history, findings, procedures, and  
99 laboratory test results. The EHR are de-identified in accordance with the Health Insurance Portability and  
100 Accountability Act (HIPAA) and the Health Information Technology for Economic and Clinical Health  
101 (HITECH) Act standards. After the de-identification process, the HGD server normalizes the data to facilitate  
102 search using the clinical ontologies from the United Medical Language System (UMLS) [21]. Specifically,  
103 systematized nomenclature of medicine – clinical terms (SNOMED-CT) are used to map disease diagnoses,  
104 clinical findings, procedures, and pharmacological drug classes [22]; individual drug names are mapped into  
105 RxNorm [23], and lab results and measurements are mapped into logical observation identifiers names and codes  
106 (LOINC) [24]. For HIPAA-compliant, statistical de-identification, the IBM Watson Health Explorys Cohort  
107 Discovery platform does not report cohort counts less than 10. At the time of the study, the Explorys Cohort  
108 Discovery platform contained over 64 million unique patients among which nearly 56 million were over 18 years  
109 of age (21 % of the U.S. population).

### 110 **Study population**

111 Patients were drawn from the Explorys platform and categorized based on their disease diagnoses and medication  
112 history. We defined patients as having Alzheimer’s disease if they had any encounter diagnosis in their  
113 contributing EHR of Alzheimer’s disease based on the SNOMED-CT disease name. A similar method was  
114 applied for identifying patients with the broader diagnosis of dementia. Since Alzheimer’s disease is a  
115 subdiagnosis of dementia within SNOMED-CT, the group of patients with dementia included all patients with a

116 diagnosis of dementia (**Table 1**). SNOMED-CT disease names also were used to identify patients diagnosed with  
117 one of eight inflammatory diseases: rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis,  
118 inflammatory bowel disease, ulcerative colitis, and Crohn’s disease. Inflammatory bowel disease is a SNOMED-  
119 CT diagnostic category that includes all patients with the subdiagnosis of ulcerative colitis but excludes patients  
120 with Crohn’s disease. Patients diagnosed with more than one inflammatory disease were excluded from the  
121 analysis. For example, a patient diagnosed with rheumatoid arthritis who also was diagnosed with ankylosing  
122 spondylitis, psoriasis, psoriasis with arthropathy, inflammatory bowel disease, ulcerative colitis, or Crohn’s  
123 disease was excluded from the analysis. The effects of each inflammatory disease on Alzheimer’s disease or  
124 dementia were compared to a non-inflammatory disease group that comprised patients who had no diagnosis of  
125 any of the eight inflammatory diseases.

126 A patient was considered “taking a medication” if at least one outpatient prescription for the medication had been  
127 written for the patient. Patients who took a drug treatment were identified by searching the generic drug names.  
128 The Explorys Cohort Discovery platform has standardized all drug names to their generic names based on  
129 RxNorm. There are five TNF blocking agents that have been approved by US Food and Drug Administration  
130 (FDA): etanercept, adalimumab, infliximab, certolizumab pegol, and golimumab. Sufficient numbers of subjects  
131 (at least 10 patients in each cell in a two by two table for at least one strata) were available to study the effects of  
132 etanercept, adalimumab, and infliximab. For the analysis, subjects were included if they were treated with a single  
133 TNF blocker but were excluded if they were treated with two or more TNF blocking drugs. For example, in the  
134 etanercept group, patients who also were prescribed adalimumab, infliximab, certolizumab pegol, or golimumab  
135 were excluded. Similarly, in the methotrexate group, patients who also were prescribed at least one of the TNF  
136 blocking agents were excluded. The effects of the TNF blockers were assessed with and without a prescription  
137 history for methotrexate. The effects of each drug treatment on the risk for Alzheimer’s disease or dementia  
138 including Alzheimer’s disease were compared to a control group of patients who did not have prescriptions for  
139 any TNF blocking agents or for methotrexate. **Figure 1** is a screenshot that illustrates how the Explorys Cohort

140 Discovery platform was used to perform cohort identification for the case-control study using the Explore fast  
141 search tool.

## 142 **Statistical Analysis**

143 The crude Odds Ratio (OR), 95% Confidence Interval (CI), and *P*-values were calculated using the Fisher exact  
144 test in univariate analysis. The Adjusted OR (AOR), 95% CI and *P*-values were calculated using the Cochran-  
145 Mantel-Haenszel (CMH) method by controlling for confounding factors such as age, gender, and race [25].

146 Statistical tests were conducted with significance set at *P*-value < 0.05 (two-sided).

147 To compute the AORs of dementia for the drug use group versus the corresponding non-drug use group, or for the  
148 inflammatory disease group versus the non-inflammatory disease group, we first calculated the OR for each of the  
149 8 strata (tabulation of 2 age groups: 18-65, and >65 years; 2 genders: male and female; and 2 races: Caucasian and  
150 Non-Caucasian) and then calculated the weighted average across all strata using the CMH method [25]. The AOR  
151 comparing the drug use group versus the non-drug use group were calculated separately in patients with a  
152 diagnosis code of rheumatoid arthritis and psoriasis. There were not enough patients (at least one cell in a two by  
153 two table have counts lower than 10 for all the strata) to test the effect of TNF blocking agents in patients with the  
154 other inflammatory diseases. To assess the effects of gender, age, and race on the risk associations between the  
155 therapeutic drugs and dementia, we separately calculated the crude OR of dementia among the 2 age groups, 2  
156 gender groups, and 2 race groups. To adjust for methotrexate prescription status in psoriasis patients, we  
157 separately calculated the crude OR for a diagnosis of Alzheimer's disease or dementia among 16 strata (tabulation  
158 of 2 age groups, 2 gender groups, 2 race groups, and 2 methotrexate groups (history of methotrexate or no  
159 methotrexate) and then calculated the weighted average across all strata using the CMH method [25].

160 Similarly, the AOR of co-morbid Alzheimer's disease for each inflammatory disease group versus the control no-  
161 inflammatory disease group were calculated by weighted average across all 8 strata. The AOR comparing the  
162 drug use group with non-drug use group on Alzheimer's disease were only calculated among patients > 65 years  
163 due to the limited sample size for patients <65 years that were diagnosed with both Alzheimer's disease and a

164 TNF-related inflammatory disease. Specifically, the AORs of Alzheimer’s disease were the weighted average of  
165 OR across all 4 strata (tabulation 2 genders: male and female; and 2 races: Caucasian and non-Caucasian) using  
166 the CMH method [25].

167 We used patient insurance types (e.g., Medicaid, Medicare, private insurance) as a proxy for their socioeconomic  
168 status. We calculated the AOR of dementia by taking the insurance status into account. We performed this  
169 procedure for patients with age between 18-65 and patients with age > 65 years old separately, since the majority  
170 of patients with age > 65 use Medicare insurance. For patients 18 - 65 years old, the AOR were calculated by  
171 controlling for gender (male and female), race (Caucasian and non-Caucasian), and insurance status (private  
172 versus no-private insurance). For patients > 65 years old, the AOR were calculated by controlling for gender  
173 (male and female), race (Caucasian and non-Caucasian), and insurance status (Medicare versus no-Medicare).

## 174 **Results**

### 175 **Structure of the Study Population**

176 The IBM Watson Health Explorys Cohort Discovery platform contained EHR from 55,902,250 unique adult  
177 patients ( $\geq 18$  years of age) at the time of the study. The baseline characteristics of the study population are  
178 presented in **Table 1**. The proportion of female patients is slightly higher than the proportion of male patients  
179 (54.88% versus 44.80%), while only a small proportion of patients (176,170: 0.32%) have a missing value for  
180 gender. The proportion of Caucasian patients is higher than non-Caucasians (57.75% versus 42.25%). Patients  
181 between 18-65 years (70.25%) are the majority age group while only a small proportion of patients (870,670:  
182 1.56%) have a missing value for age. 35.51% (19,851,070) of adult patients have private insurance, while  
183 12.61% (7,048,160) are enrolled in Medicare and 6.16% (3,448,710) receive Medicaid. Since the majority of  
184 patients older than 65 years in the US transition from private insurance to Medicare, the Explorys Cohort  
185 Discovery platform contains a study population that represents the general US population and the age-dependent  
186 prevalence of Alzheimer’s disease due to the inclusion of Medicare patients. Patients with missing values for  
187 gender or age were excluded when performing statistical analysis.

188 In the absence of confirmatory brain imaging for amyloid or tau, or pathology post-mortem, the diagnosis of  
189 Alzheimer's disease is a clinical diagnosis made by a physician based on an interview and cognitive assessment.  
190 Even with carefully selected patients enrolled in large, multi-center, Phase 3 clinical trials, Alzheimer's disease is  
191 misdiagnosed based solely on clinical criteria in up to 25% of patients [26, 27]. In a database such as the  
192 Explorys Cohort Discovery platform that aggregates EHR from large, integrated health delivery systems and  
193 community-based networks, the rate of misdiagnosis of Alzheimer's disease may be even higher. Therefore, we  
194 structured our analysis to proceed in two stages. We first calculated the AOR for a SNOMED-CT diagnosis of  
195 Alzheimer's disease and second, expanded the analysis using the SNOMED-CT diagnosis of dementia. Within  
196 SNOMED-CT, dementia is a general diagnostic term that includes all patients with a specific diagnosis of  
197 Alzheimer's disease. Within our study population, 338,400 (0.60%) patients were diagnosed with Alzheimer's  
198 disease while 999,800 (1.79%) patients were diagnosed with dementia including Alzheimer's disease. In  
199 addition to Alzheimer's disease, the SNOMED-CT diagnosis of dementia includes subdiagnoses of presenile  
200 dementia, mild, mixed, moderate and severe dementia, dementia associated with human immunodeficiency virus  
201 infection, and frontal temporal lobe dementia, but excludes dementia associated with Huntington's disease,  
202 Parkinson's disease, Rett's syndrome and vascular dementia. The prevalence of Alzheimer's disease in the 2018  
203 US population is estimated at about 2% of persons older than 18 years, so the Explorys study population of  
204 dementia including Alzheimer's disease approximates the prevalence of Alzheimer's disease in the US [28].  
205 Based on prescription history, a substantial number of patients with suspected Alzheimer's disease are likely  
206 classified within the Explorys Cohort Discovery platform with a diagnosis of dementia. For example, the  
207 approved uses of the cholinesterase inhibitors (donepezil, galantamine, and rivastigmine) and memantine by the  
208 US Food and Drug Administration (FDA) are for treating mild, moderate or severe dementia of the Alzheimer's  
209 type. Rivastigmine has an additional FDA approval for use in mild-to-moderate dementia associated with  
210 Parkinson's disease. Of 338,400 patients with a diagnosis code for Alzheimer's disease, 172,750 (51%) received  
211 at least one prescription for a cholinesterase inhibitor or memantine, while an additional 157,850 patients with a  
212 diagnosis code for dementia were also treated with at least one drug approved for Alzheimer's disease (24%). A

213 high proportion of these patients likely represent cases of dementia due to suspected Alzheimer's disease.  
214 Querying more broadly in the Explorys Cohort Discovery platform for any use of a cholinesterase inhibitor or  
215 memantine, 145,860 patients were prescribed at least one of the four drugs without a SNOMED-CT diagnosis of  
216 dementia or Alzheimer's disease. This included 9,540 patients with a diagnosis code for Parkinsonism,  
217 3,900 with a diagnosis code for degenerative disease of the central nervous system, and 3,990 patients with a  
218 diagnosis code for traumatic brain injury. Thus, Explorys captures both approved and off-label use of  
219 prescription drugs.

### 220 **Risk for Alzheimer's Disease is Increased by Systemic Inflammation**

221 We hypothesized that systemic inflammatory diseases which in part are mediated by TNF increase the risk for  
222 Alzheimer's disease. We therefore selected for study those inflammatory diseases for which a TNF blocking  
223 agent is an FDA approved treatment [5]. Approved indications include rheumatoid arthritis, ankylosing  
224 spondylitis, psoriasis, psoriatic arthritis, inflammatory bowel disease, ulcerative colitis, and Crohn's disease.  
225 Five TNF blocking agents have been approved by FDA, of these, sufficient patients were prescribed etanercept  
226 (44,210 patients), adalimumab (66,820 patients), and infliximab (40,290) to allow inclusion in the retrospective,  
227 case-control study. In addition, 161,560 patients received at least one prescription for methotrexate but had not  
228 been treated with a TNF blocking agent. Methotrexate is a small molecule inhibitor of immune cell activation  
229 that suppresses systemic TNF [29]. In normal clinical practice, patients are started on methotrexate and those  
230 who fail methotrexate may progress to a treatment with a TNF blocking agent. Of those who progress to the TNF  
231 blocking agent, 60% will continue on methotrexate and 40% will drop the methotrexate [29, 30].

232 The cumulative age distribution for patients with a diagnosis code for rheumatoid arthritis, dementia or  
233 Alzheimer's disease is shown in **Figure 2**. Given that the Explorys Cohort Discovery platform includes at least  
234 some information on patients making up over 20% of the US population, the cumulative age distribution should  
235 reasonably represent the age-dependent prevalence of these diseases in the US. As expected, the age distribution  
236 of patients with a diagnosis of rheumatoid arthritis skews younger, while patients with dementia or Alzheimer's  
237 disease skew older. The average treatment retention time varies among the three TNF blocking agents selected

238 for study with etanercept having a better than 50% patient retention rate at 12 years of treatment, while the 50%  
239 retention rates for adalimumab and infliximab are about 2 and 3 years, respectively [30, 31]. To comply with  
240 HIPAA compliant de-identification of EHR, the Explorys Cohort Discovery platform does not allow patient level  
241 access to prescription data. Therefore, we compared the benefit of etanercept to adalimumab and infliximab as a  
242 surrogate for duration of exposure as a modifier of treatment benefit.

243 Systemic inflammatory disease is a substantial risk factor for Alzheimer's disease (**Figure 3**). Greatest risk is  
244 associated with inflammatory bowel disease and Crohn's disease followed by rheumatoid arthritis, ulcerative  
245 colitis (as a subcategory of inflammatory bowel disease), ankylosing spondylitis and psoriasis. There is no  
246 additional risk associated with psoriatic arthritis. Inflammatory bowel disease, Crohn's disease and rheumatoid  
247 arthritis increase the risk for Alzheimer's disease over two-fold (AOR 2.06 (2.02-2.10) – AOR 2.46 (2.33-2.59)).  
248 The increased risk contributed by systemic inflammation was replicated in patients with a diagnosis code for  
249 dementia in which Alzheimer's disease is a subcategory (**Figure 4**). Risk for dementia was elevated two-fold in  
250 patients with rheumatoid arthritis, inflammatory bowel disease, ankylosing spondylitis, ulcerative colitis and  
251 Crohn's disease (AOR 2.00 (1.94-2.06) -AOR 2.69 (2.66-2.72)). Psoriasis also increased risk for Alzheimer's  
252 disease and dementia although to a lesser extent (AOR 1.37 (1.31-1.42) and AOR 1.49 (1.46 – 1.53),  
253 respectively). Thus, systemic inflammation increases risk for Alzheimer's disease across multiple diseases  
254 involving the joints, the gut and the skin.

### 255 **TNF Blocking Agents Reduce Risk for Alzheimer's Disease in Patients with Systemic Inflammation**

256 If the increased risk for Alzheimer's disease is associated with TNF, then TNF blocking agents should reduce risk  
257 for Alzheimer's disease in patients with co-morbid inflammatory disease. Since TNF blocking agents frequently  
258 are prescribed as an add-on to methotrexate, we compared subjects who received a TNF blocking agent without  
259 methotrexate with those who received the TNF blocking agent and methotrexate. Treatment of rheumatoid  
260 arthritis with etanercept, adalimumab, or infliximab significantly reduced the risk for Alzheimer's disease with  
261 etanercept and adalimumab having the greatest benefit (AOR 0.34 (0.25 – 0.47) and AOR 0.28 (0.19 – 0.39),  
262 respectively), **Figure 5**. The benefit of etanercept and adalimumab was replicated in patients with a diagnosis

263 code of dementia (AOR 0.30 (0.26 – 0.35) and AOR 0.35 (0.30 – 0.41), respectively). Etanercept and  
264 adalimumab have similar benefit even though the treatment retention time with etanercept (50% at 12 years) is  
265 considerably longer than adalimumab (50% at 2 years) [30, 31]. Infliximab had slightly greater benefit than  
266 methotrexate, but methotrexate alone significantly reduced risk for Alzheimer’s disease and dementia (AOR 0.52  
267 (0.39 – 0.69) and AOR 0.64 (0.61 – 0.68), respectively), **Figure 5**. We therefore asked if the benefit of the TNF  
268 blocking agents replicated in patients with a prescription history of a TNF blocker and methotrexate compared to  
269 methotrexate alone. Etanercept and adalimumab had similar benefit in reducing risk for co-morbid Alzheimer’s  
270 disease in patients who also had a prescription history for methotrexate (AOR 0.53 (0.42 – 0.67) and AOR 0.61  
271 (0.49 – 0.77), respectively) while the benefit of infliximab was less (AOR 0.77 (0.63 – 0.67), **Figure 6**.

272 Reduction of risk for Alzheimer’s disease also was seen in psoriasis patients treated with a TNF blocking agent  
273 (**Figure 7**). Etanercept (AOR 0.47 (0.30 – 0.73) and adalimumab (AOR 0.41 (0.20 – 0.76) significantly reduced  
274 risk for Alzheimer’s disease in patients with psoriasis and the benefit of adalimumab (AOR 0.54 (0.44 – 0.66) was  
275 replicated when expanded to patients with a diagnosis code for dementia (**Figure 7**). Infliximab and methotrexate  
276 had no benefit. A substantial number of psoriasis patients had a prescription history of a TNF blocker with  
277 methotrexate. Methotrexate alone did not reduce risk for Alzheimer’s disease, nor did use of a TNF blocker  
278 provide additional benefit adjusting for methotrexate prescription status beyond the benefit of etanercept or  
279 adalimumab alone (AOR 0.53 (0.37 – 0.76) and AOR 0.50 (0.32 – 0.78), **Figure 8**. The Explorys Cohort  
280 Discovery platform does not permit access to patient level data, so a limitation of this analysis is that we do not  
281 know if the TNF blocker was prescribed as an add-on to methotrexate or if the two drugs were prescribed  
282 sequentially with methotrexate dropped once treatment with the TNF blocker was started.

283 We separately assessed the effects of gender, age, and race on the effect of TNF blocking agents on the risk of  
284 dementia among patients with rheumatoid arthritis. Data are shown for etanercept in **Figure 9**. Female and male  
285 patients had a similar benefit when treated with etanercept ( $P = 0.14$ ), adalimumab ( $P = 0.14$ ), or infliximab ( $P =$   
286  $0.71$ ). There was a significant difference in benefit when comparing Caucasian versus non-Caucasian patients  
287 with a prescription history for etanercept ( $P = 0.022$ ) but not for adalimumab ( $P = 0.34$ ) or infliximab ( $P =$

288 0.078). Interestingly, the risk reduction was greatly increased for younger patients (18-65 years) as compared to  
289 older patients (> 65 years) with AOR 0.16 (0.11 – 0.22) in younger patients as compared to AOR 0.40 (0.34 –  
290 0.46) in older patients (**Figure 9**). Greater benefit also was seen in younger patients prescribed adalimumab ( $P =$   
291 0.022) or infliximab ( $P = 0.00026$ ) as compared to older patients.

292 We also explored insurance status as a potential confound for age (comparing younger patients with private  
293 insurance as compared to patients over 65 years with Medicare) and socioeconomic status (patients with Medicaid  
294 or private insurance). There was no difference between patients with private insurance as compared to Medicare,  
295 nor does adjusting insurance status influence the effect of TNF blockers on the risk for dementia (**Figure 10**).  
296 There were too few patients with Medicaid and Alzheimer’s disease (21,030, 6.2%) or Medicaid and a diagnosis  
297 of dementia (84,040, 8.4%) for analysis (**Table 1**).

298 Finally, we sought to understand if treatment with a TNF blocking agent simply reduced the additional risk for  
299 Alzheimer’s disease contributed by a co-morbid inflammatory disease, or if the TNF blocking agent could reduce  
300 risk for Alzheimer’s disease below the risk in the general population in the absence of inflammatory disease as a  
301 risk factor and excluding a prescription history for a TNF blocker or methotrexate. Indeed, the risk for  
302 Alzheimer’s disease was reduced below the general population risk in rheumatoid arthritis patients treated with  
303 adalimumab (AOR 0.62 (0.43 – 0.89) and in psoriasis patients treated with etanercept (AOR 0.58 (0.37 – 0.90) or  
304 adalimumab (AOR 0.48 (0.23 – 0.88), **Figure 11**. The benefit of adalimumab also replicated for reduction of risk  
305 in psoriasis patients with a diagnosis code for dementia (AOR 0.82 (0.67 – 1.00), **Figure 11**).

## 306 **Discussion**

307 This study shows that inflammatory diseases involving TNF are associated with increased risk for Alzheimer’s  
308 disease. Patients with rheumatoid arthritis, inflammatory bowel disease, or Crohn’s disease are at highest risk for  
309 Alzheimer’s disease. For rheumatoid arthritis and psoriasis, treatment with a biologic drug that targets TNF  
310 correspondingly reduces the risk for Alzheimer’s disease.

311 This case-control analysis provides an assessment of the additional risk for Alzheimer's disease that can be  
312 attributed to co-morbid inflammatory disease involving TNF. Although there are genetically-defined subgroups  
313 at high risk for Alzheimer's disease, for example, patients with highly penetrant, autosomal dominant APP, PS1  
314 or PS2 mutations,[1] late-onset Alzheimer's disease generally is viewed as a heterogenous disease with multiple  
315 genetic, medical and environmental risk factors [2, 32]. Our analysis suggests that co-morbid inflammatory  
316 disease defines a subgroup of Alzheimer's patients in which systemic production of TNF contributes to  
317 pathogenesis. Systemic TNF may promote neuroinflammation in the brain through receptor-mediated  
318 transcytosis [12]. Biologic drugs such as etanercept and adalimumab distribute poorly to brain, so we presume  
319 the TNF blockers act systemically to prevent TNF from reaching the brain and thereby prevent or delay the onset  
320 of Alzheimer's disease.

321 Our study indicates that systemic inflammatory conditions involving TNF are a potentially treatable risk factor for  
322 Alzheimer's disease. This is a small, but potentially treatable subgroup of people at risk for Alzheimer's disease.  
323 The total number of patients with Alzheimer's disease in the US is estimated to be 5.3 million in 2018 [28].  
324 Based on our estimate of population attributable risk, 0.21 million cases (4.04%) of Alzheimer's disease might be  
325 preventable by treating rheumatoid arthritis with a TNF blocking agent, 0.08 million cases (1.51%) of  
326 Alzheimer's disease might be preventable by treating Crohn's disease with a TNF blocking agent, and 0.026  
327 million cases (0.50%) of Alzheimer's disease might be preventable by treating psoriasis with a TNF blocker or  
328 nearly 6% of cases of Alzheimer's disease.

329 Etanercept previously was evaluated in a small, placebo-controlled study enrolling 41 patients with mild-to-  
330 moderate Alzheimer's disease [33]. End points in the study assessed improvement in cognitive function and  
331 activities of daily living. There was a trend for etanercept benefit at 24 weeks of treatment across multiple  
332 assessments. These results are encouraging given the small size of the clinical trial and support further study of  
333 the treatment benefit of etanercept in symptomatic Alzheimer's disease. Etanercept also was evaluated in a small,  
334 open label clinical trial in Alzheimer's disease with report of clinical benefit [34], while therapeutic benefit was  
335 reported earlier for reducing risk of major depression in a pivotal, Phase 3 clinical trial of etanercept for the

336 treatment of psoriasis [35]. A previous study also suggested that TNF blocking agents are associated with  
337 decreased incidence of co-morbid Parkinson disease in patients with inflammatory bowel disease [36].

338 Supporting evidence for a role of TNF in Alzheimer's disease comes from the Accelerating Medicines Partnership  
339 – Alzheimer's Disease (AMP-AD), a large-scale, precompetitive public private partnership led by the National  
340 Institute on Aging (NIA). Nominated targets with supporting evidence include multiple elements of the TNF  
341 signaling pathway such as TLR4, NFKBIA, NFKBIZ, TNFSR1A [37]. TLR4 encodes the Toll like receptor 4, a  
342 receptor in microglia, monocytes and macrophages that triggers TNF release when activated by  
343 lipopolysaccharide, or in the case of microglia, by amyloid beta peptide [32]. TLR4 and a second Toll-like  
344 receptor, TLR5, are upregulated in the Alzheimer's brain and soluble fragments have been shown to act as decoy  
345 receptors to ameliorate disease phenotypes in a transgenic mouse model of Alzheimer's disease [38]. NFKBIA  
346 and NFKBIZ are components of the nuclear I kappa B protein signaling pathway that regulates the expression of  
347 TNF while TNFSR1A encodes the TNF receptor superfamily member 1A that is activated by TNF [39].

348 Microglia activation and gliosis formerly were considered secondary to neurodegeneration in Alzheimer's  
349 disease, however, recent genetic studies in late-onset Alzheimer's disease implicate microglia- and astrocyte-  
350 related pathways in disease pathogenesis.[10, 40, 41] One focus of interest is TREM2, an innate immune receptor  
351 expressed on microglia and myeloid cells [42, 43] . Rare TREM2 mutations associated with Alzheimer's disease  
352 suggest that TREM2 deficiency contributes to Alzheimer's disease risk [44, 45]. TREM2 is a negative regulator  
353 of the release of TNF and other inflammatory cytokines through activation of the Toll-receptor pathway [8, 43,  
354 46].

355 TNF signaling can be targeted by small molecule therapeutics [7, 9, 47]. For example, this pathway is modulated  
356 in monocytes, macrophages and microglia by phosphodiesterase-4B (PDE4B) [48, 49], while treatment with a  
357 PDE4B allosteric inhibitor after acute brain injury reduces microglial activation, reduces production of TNF, and  
358 provides neuroprotective benefit in rats [50]. Small molecule drugs targeting the TLR4-TNF pathway may  
359 produce greater therapeutic benefit than large, biologic drugs for which brain penetration may be limited.

360 Epidemiologic studies previously suggested that non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the  
361 risk for Alzheimer's disease [51]. In a case-control study of 49,349 US Veterans, protective effects were seen with  
362 ibuprofen, naproxen and other NSAIDs with > 5 years of use (OR 0.76 [0.68-0.85]). Use of an NSAID was most  
363 frequently associated with osteoarthritis (46-48% of cases and controls). The risk reduction associated with use of  
364 an NSAID was less than the risk reduction of Alzheimer's disease due to use of methotrexate in patients with  
365 rheumatoid arthritis (OR 0.51 [0.49-0.54]), **Figure 3**. Multiple randomized, placebo-controlled clinical trials have  
366 failed to show benefit of treatment with an NSAID in prodromal or symptomatic Alzheimer's disease [52-54].  
367 NSAIDs are one of three categories of therapeutics used to treat rheumatoid arthritis.[5] The other categories are  
368 corticosteroids and disease-modifying antirheumatic drugs (DMARDs). NSAIDs are used for the control of pain  
369 and inflammation while corticosteroids and DMARDs are used to reduce the cellular immune response that leads  
370 to destruction of the joint. NSAIDs suppress prostaglandin synthesis by inhibiting the cyclooxygenase enzymes  
371 COX-1 and COX-2, and thereby reduce immune cell activation, but may increase TNF production [47, 55]. The  
372 lack of efficacy seen with NSAIDs in Alzheimer's disease may be associated with the lack of a strong suppressive  
373 effect on TNF production. Low dose prednisone (10 mg/day) is used to treat rheumatoid arthritis, presumably by  
374 suppressing immune activation and TNF production, but long term use is associated with increasingly  
375 unacceptable side effects. Treatment with low dose prednisone for 1 year failed to show benefit in patients with  
376 mild-to-moderate Alzheimer's disease [56].

### 377 **Strengths and Limitations**

378 The strength of the current study is that the massive-scale of the EHR database allowed us to access real-world  
379 patient populations. With 64 million unique patient EHR, the IBM Watson Health Explorys Cohort Discovery  
380 platform has aggregated the medical records from approximately 20% of the US population. Such a massive  
381 database covers the full spectrum of disease diagnoses and the use of prescription drugs for both approved and  
382 off-label indications. Access to large data sets is particularly useful in the case of Alzheimer's disease where a  
383 substantial fraction of patients in a clinical setting are either misdiagnosed as having the disease when they do not  
384 or for whom the physician is unwilling to make a specific diagnosis even though Alzheimer's disease is suspected

385 and an approved medication for Alzheimer’s disease is prescribed. This allowed us to test for the association of  
386 co-morbid Alzheimer’s disease with systemic inflammatory disease and to test the benefit of TNF blocking agents  
387 by first selecting patient cohorts with a specific diagnosis of Alzheimer’s disease and then by replicating that  
388 finding in a larger cohort of patients with dementia which better reflects the uncertainty of the diagnosis of  
389 Alzheimer’s disease in a community health setting.

390 The scale of the Watson Health Explorys Cohort Discovery platform allowed us to maintain adequate statistical  
391 power while we studied disease association and the benefit of TNF blockers across multiple inflammatory  
392 diseases. This often is difficult in traditional observational studies which frequently are limited in sample size.  
393 Compared to the private insurance database used in the previous study [13], the Explorys Cohort Discovery  
394 platform contains a study population that includes patients with private insurance and Medicare. This is  
395 particularly critical for the study of diseases that primarily affect an elderly population as the majority of patients  
396 older than 65 years in the US transition from private insurance to Medicare.

397 The current study has limitations. First, the quality or incompleteness of the EHR for individual patients may  
398 affect the sensitivity and specificity of the analysis and misdiagnosis will contribute to false positives and false  
399 negatives within the patient cohorts selected for study. Second, the retrospective case-control analysis suggests a  
400 potential therapeutic benefit of TNF blocking agents in Alzheimer’s disease, however, the analysis does not  
401 distinguish an effect on treatment of prevention, nor does our analysis address how the severity of disease may  
402 influence benefit. A limitation of the Explorys Cohort Discovery platform is the inability to access patient level  
403 data for reasons of confidentiality. We are unable to extract age at diagnosis, duration of treatment, or years of  
404 follow up which are potential confounding factors to this analysis, nor are we able to build an exposure-response  
405 relationship for the reduction in risk due to use of a TNF blocking agent. Due the fact that we used population-  
406 level data, we relied on the odds ratio for the statistical analysis and cannot calculate an incidence rate ratio [36].  
407 Additionally, the Explorys Cohort Discovery platform considers patients to be “taking a medication” if at least on  
408 outpatient prescription has been written for the medication, but does not record if medications were prescribed  
409 sequentially after the first drug failed, or whether two or more medications were prescribed concurrently. These

410 potential confounds may lead our findings to underrepresent the “true findings.” Without access to patient level  
411 data, we were only able to control for known confounding factors using the Cochran-Mantel-Haenszel (CMH)  
412 method [25] instead of systematically identifying and controlling for potential confounding factors using a more  
413 rigorous multivariable regression method. Even with these limitations, the results of our study are consistent with  
414 a previous study using patient-level data [13] and with a unpublished study reported in the popular press. As  
415 shown in **Table 2**, the therapeutic benefit of etanercept on risk for co-morbid Alzheimer’s disease that we report  
416 in patients with rheumatoid arthritis is consistent with a previous case-control analysis of 8.5 million privately  
417 insured patients [13] and with an unpublished study that reportedly analyzed claims data from 254,000 patients.  
418 Thus, our study conducted with a massive EHR database is consistent with smaller studies conducted with  
419 patient-level data collected using private insurance claims databases.

## 420 **Conclusions**

421 Our analysis demonstrates the value of a large, population-based database aggregating EHR from nearly 56  
422 million adult patients for the rapid interrogation of the treatment benefit of prescription drugs. Patients diagnosed  
423 with a systemic inflammatory disease are at increased risk for developing Alzheimer’s disease, while TNF  
424 blocking agents reduce the risk for co-morbid Alzheimer’s disease in real-world patients diagnosed with  
425 rheumatoid arthritis or psoriasis.

## 426 **Author Information**

## 427 **Author Contributions**

428 M.Z. conducted the statistical analysis. R.X. designed the study. D.C.K contributed to the manuscript. M.E.G.  
429 coauthored the manuscript.

## 430 **Acknowledgements**

431 The authors thank Dr Susan Petanscka PhD, Dr Scott Reines MD PhD and Dr Richard Martin MD for their  
432 comments on the design of the study.

433 **Conflict of Interest Disclosures**

434 M.Z., R.X. and M.E.G have no financial interest in etanercept, adalimumab, or infliximab. M.E.G is an employee  
435 of Tetra Therapeutics.

436 **Funding/Support**

437 R.X. acknowledges support from Eunice Kennedy Shriver National Institute of Child Health & Human  
438 Development of the National Institutes of Health under the NIH Director’s New Innovator Award number  
439 DP2HD084068, NIH National Institute of Aging R01 AG057557, R01 AG061388, R56 AG062272 and American  
440 Cancer Society Research Scholar Grant RSG-16-049-01 – MPC; M.E.G. is an employee of Tetra Discovery  
441 Partners, Inc. and acknowledges support from the National Institute of Mental Health awards MH091791 and  
442 MH107077.

443 **Role of the Funder/Sponsor:** The funding sources had no role in the design and conduct of the study; collection,  
444 management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and  
445 decision to submit the manuscript for publication.

446 **Meeting Presentation:** Portions of this study were presented at the National Institute on Aging-Alzheimer’s  
447 Association symposium on “Enabling Precision Medicine For Alzheimer’s Disease Through Open Science”, July  
448 11-July 12, 2019, Los Angeles, California.

449 **OCRID ID**

450 Rong Xu: 0000-0003-3127-4795

451 Mark Gurney: 0000-0003-4901-3083

452

453

454

455 **Tables**

456 **Table 1.** Baseline characteristics of the study population

<b>Patient Characteristics</b>	<b>Study Population</b>	<b>Alzheimer's Disease</b>	<b>Dementia</b>
<b>Total No. of patients</b>	55,954,070	338,400	999,800
<b>Gender (Number (%))</b>			
Female	30,708,300 (54.88)	216,530 (63.99)	605,350 (60.55)
Male	25,069,350 (44.80)	121,770 (35.98)	394,110 (39.42)
Unknown	176,410 (0.32)	100 (0.030)	330 (0.030)
<b>Age (Number (%))</b>			
Adult (18 to 65)	39,294,220 (70.23)	13,300 (3.93)	151,130 (15.12)
Senior (> 65)	15,788,180 (28.22)	308,930 (91.29)	810,180 (81.03)
Unknown	850,590 (1.52)	16,120 (4.76)	38,230 (3.82)
<b>Race (Number (%))</b>			
Caucasian	32,209,260 (57.56)	263,850 (77.94)	773,810 (77.40)
Non-Caucasian	23,744,810 (42.44)	74,560 (22.03)	225,990 (22.60)
<b>Insurance (Number (%))</b>			
Private	19,854,540 (35.48)	112,350 (33.20)	351,420 (35.15)
Medicare	7,047,380 (12.59)	213,760 (63.17)	578,670 (57.88)
Medicaid	3,448,710 (6.16)	21,030 (6.21)	84,040 (8.41)
<b>Diagnoses (Number (%))</b>			
Rheumatoid arthritis	514,440 (0.92)	16,280 (4.81)	47,270 (4.73)
Ankylosing spondylitis	35,550 (0.060)	460 (0.14)	1,620 (0.16)
Psoriasis	309,660 (0.55)	3,340 (0.99)	10,500 (1.05)
Psoriatic arthritis	80,580 (0.14)	650 (0.19)	2,220 (0.22)
Inflammatory bowel disease	279,040 (0.50)	4,440 (1.31)	13,770 (1.38)
Ulcerative colitis	168,870 (0.30)	2,650 (0.78)	8,220 (0.82)
Crohn's disease	201,870 (0.36)	6,160 (1.82)	12,270 (1.23)
<b>Drugs (Number (%))</b>			
Etanercept	44,210 (0.080)	250 (0.070)	1,080 (0.11)
Adalimumab	66,820 (0.12)	320 (0.090)	1,260 (0.13)
Infliximab	40,290 (0.070)	340 (0.10)	1,100 (0.11)
Methotrexate	216,200 (0.39)	2,850 (0.84)	9,550 (0.96)

457

458

459 **Table 2:** Comparison of etanercept, adalimumab, and infliximab benefit across studies.

Study	Sample size	Outcome	TNF Blockers	OR	P-value
Chou 2016 [13]	8.5 million	Alzheimer's disease	etanercept	0.30	0.02
The Washington Post <sup>§</sup>	254,000	Alzheimer's disease	etanercept	0.36	<0.0001
Our study	56 million	Alzheimer's disease	etanercept	0.34	<0.0001
Our study	56 million	Dementia	etanercept	0.30	<0.0001
Chou 2016 [13]	8.5 million	Alzheimer's disease	adalimumab	0.65	0.71
Our study	56 million	Alzheimer's disease	adalimumab	0.28	<0.0001
Our study	56 million	Dementia	adalimumab	0.35	<0.0001
Chou 2016 [13]	8.5 million	Alzheimer's disease	infliximab	0.73	0.68
Our study	56 million	Alzheimer's disease	infliximab	0.64	<0.0001
Our study	56 million	Dementia	infliximab	0.47	<0.0001

460 <sup>§</sup>[https://www.washingtonpost.com/business/economy/pfizer-had-clues-its-blockbuster-drug-could-prevent-  
alzheimers-why-didnt-it-tell-the-world/2019/06/04/9092e08a-7a61-11e9-8bb7-0fc796cf2ec0\\_story.html](https://www.washingtonpost.com/business/economy/pfizer-had-clues-its-blockbuster-drug-could-prevent-461 alzheimers-why-didnt-it-tell-the-world/2019/06/04/9092e08a-7a61-11e9-8bb7-0fc796cf2ec0_story.html)

462

463 **Figures**

464 **Figure 1.** A screen shot of cohort identification using the IBM Watson Health Explorers Cohort Discovery fast  
465 search tool. This example selects female Caucasian patients with age > 65 years with a diagnosis code for  
466 dementia and a prescription for etanercept (Enbrel).

467

**Fast Search**

Explore:

Alzheimer's disease

- Diagnosis: **Alzheimer's disease**
- Diagnosis: **Disease**
- Diagnosis: Neoplastic **disease**
- Diagnosis: Malignant neoplastic **disease**
- Diagnosis: Infectious **disease**
- Diagnosis: Congenital **disease**
- Diagnosis: Heart **disease**
- Diagnosis: Acute **disease**
- Diagnosis: Bacterial infectious **disease**
- Diagnosis: Chronic **disease**
- Diagnosis: Viral **disease**
- Diagnosis: Kidney **disease**
- Diagnosis: Sequelae of inflammatory **diseases**
- Diagnosis: Neoplastic **disease** of uncertain behavior
- Diagnosis: Secondary malignant neoplastic **disease**

[Suggest a search improvement](#)

Show items with 100%

Page

Diagnoses | **Drugs** | Procedures | Vitals

	Count	Proportion
Diagnosis: Alzheimer's disease	80	21%
Diagnosis: Disease	80	21%
Diagnosis: Neoplastic disease	80	21%
Diagnosis: Malignant neoplastic disease	70	18%
Diagnosis: Infectious disease	50	13%
Diagnosis: Congenital disease	40	10%
Diagnosis: Heart disease		
Diagnosis: Acute disease		
Diagnosis: Bacterial infectious disease		
Diagnosis: Chronic disease		
Diagnosis: Viral disease		
Diagnosis: Kidney disease		
Diagnosis: Sequelae of inflammatory diseases		
Diagnosis: Neoplastic disease of uncertain behavior		
Diagnosis: Secondary malignant neoplastic disease		

[Export To Excel file](#)

Warning: Due to the small cohort size, Data Blurring may cause the listed percentages to not add up to 100%

**Cohort**

Population Size: 390  
Universe  
Cohort ID: 508378

**Cohort: Example**

All of these . . . (and)

- Concept**  **Option**
- Diagnosis:** Dementia  
Size: 1,008,410
- Diagnosis:** Rheumatoid arthritis  
Size: 516,360
- Drug Ingredient:** Etanercept  
Size: 44,710
- Demographic:** Female (gender)  
Size: 34,650,930
- Demographic:** Senior (age greater than 65)  
Size: 15,809,290
- Demographic:** Caucasian (race)  
Size: 36,616,970

----- AND -----


468

469

470

471 **Figure 2.** Cumulative age distribution of patients with a diagnosis code for rheumatoid arthritis, dementia or  
472 Alzheimer's disease.

473




474

475

476 **Figure 3.** Adjusted Odds Ratio (AOR) for a diagnosis of Alzheimer’s disease associated with a diagnosis for an  
 477 inflammatory disease as compared to the non-inflammatory disease group. Abbreviations: RA -rheumatoid  
 478 arthritis, AS -ankylosing spondylitis, PA -psoriatic arthritis, IBD -inflammatory bowel disease, UC -ulcerative  
 479 colitis, Crohn’s -Crohn’s disease

480




481

482

483

484 **Figure 4.** Adjusted Odds Ratio (AOR) for a diagnosis code of dementia associated with a diagnosis for an  
 485 inflammatory diseases as compared to the non-inflammatory disease group. Abbreviations: RA -rheumatoid  
 486 arthritis, AS -ankylosing spondylitis, PA -psoriatic arthritis, IBD -inflammatory bowel disease, UC -ulcerative  
 487 colitis, Crohn's -Crohn's disease.

488




489

490

491

492 **Figure 5.** Adjusted Odds Ratio (AOR) showing reduction of risk for Alzheimer’s disease or a diagnosis of  
 493 dementia in patients with a diagnosis of rheumatoid arthritis with a prescription history of a TNF blocker or  
 494 methotrexate compared to the no-drug group. The analysis excluded patients with a prescription history of a TNF  
 495 blocker and methotrexate.

496




497

498

499 **Figure 6:** Adjusted Odds Ratio (AOR) showing reduction of risk for Alzheimer’s disease or a diagnosis of  
 500 dementia in patients with a diagnosis of rheumatoid arthritis with a prescription history of methotrexate and a  
 501 TNF blocker compared to the methotrexate and no-TNF blocker group.

502




503

504

505 **Figure 7.** Adjusted Odds Ratio (AOR) showing reduction of risk for Alzheimer’s disease or a diagnosis of  
 506 dementia in patients with a diagnosis of psoriasis with a prescription history of a TNF blocker or methotrexate  
 507 compared to the no-drug group.

508

Drug	Outcome	AOR(95% CI)	P-value
Etanercept	Alzheimer	0.47 (0.30,0.73)	0.00083
Adalimumab	Alzheimer	0.41 (0.20,0.76)	0.002
Infliximab	Alzheimer	1.14 (0.54,2.14)	0.61
Methotrexate	Alzheimer	0.87 (0.75,1.01)	0.065
Etanercept	Dementia	0.90 (0.76,1.07)	0.25
Adalimumab	Dementia	0.54 (0.44,0.66)	<0.0001
Infliximab	Dementia	0.72 (0.50,1.04)	0.094
Methotrexate	Dementia	0.95 (0.87,1.03)	0.19




509

510

511 **Figure 8.** Adjusted Odds Ratio (AOR) showing reduction of risk for Alzheimer’s disease or a diagnosis of  
 512 dementia in patients with a diagnosis of psoriasis with a prescription history of a TNF blocker adjusting for  
 513 methotrexate prescription status.

514




515

516

517

518 **Figure 9.** Effect of age, gender and race on risk for a diagnosis of dementia in rheumatoid arthritis patients treated  
 519 with etanercept. Young patients (18-65 years) showed greater benefit than did older patients (over 65 years). The  
 520 effect of gender and race was not significant.

521




522

523

524 **Figure 10.** Crude Odds Ratios (OR) and Adjusted Odds Ratios (AOR) based on insurance status (Medicare versus  
 525 no-Medicare, or private versus no-private insurance) in patients with a diagnosis code for dementia and  
 526 rheumatoid arthritis.

527




528

529

530 **Figure 11.** Comparison of the risk for a diagnosis of Alzheimer’s disease or dementia in patients with a diagnosis  
 531 of rheumatoid arthritis or psoriasis with a prescription history for etanercept, adalimumab, or infliximab who were  
 532 not prescribed methotrexate against the general population.

533



534

535

536 **Supporting information**

537 S1 Table. Two by two tables for each of the strata comparing the odds for a diagnosis of Alzheimer's disease  
538 associated with a diagnosis for an inflammatory disease versus the non-inflammatory disease group.

539 S2 Table. Two by two tables for each of the strata comparing the odds for a diagnosis of dementia associated with  
540 a diagnosis for an inflammatory disease versus the non-inflammatory disease group.

541 S3 Table. Two by two tables for each of the strata comparing the odds for a diagnosis of Alzheimer's disease or  
542 dementia in patients with a diagnosis of rheumatoid arthritis with a prescription history of a TNF blocker or  
543 methotrexate versus the no-drug group. The analysis excluded patients with a prescription history of a TNF  
544 blocker and methotrexate.

545 S4 Table. Two by two tables for each of the strata comparing the odds for a diagnosis of Alzheimer's disease or  
546 dementia in patients with a diagnosis of rheumatoid arthritis with a prescription history of a TNF blocker and  
547 methotrexate versus the no-TNF blocker but with methotrexate patient group.

548 S5 Table. Two by two tables for each of the strata comparing the odds for a diagnosis of Alzheimer's disease or  
549 dementia in patients with a diagnosis of psoriasis with a prescription history of a TNF blocker or methotrexate  
550 versus the no-drug group. The analysis excluded patients with a prescription history of a TNF blocker and  
551 methotrexate.

552 S6 Table. Two by two tables for each of the strata comparing the odds for a diagnosis of Alzheimer's disease or  
553 dementia in patients with a diagnosis of psoriasis with a prescription history of a TNF blocker versus the no-drug  
554 group adjusting for methotrexate prescription status.

555 S7 Table. Two by two tables investigating the effects of age, gender and race on the association between the  
556 prescription of a TNF blocker and dementia (or Alzheimer's disease) in patients with a diagnosis code for  
557 rheumatoid arthritis.

558 S8 Table. Two by two tables calculating the insurance status-adjusted and crude ORs of dementia for each TNF  
559 blocker use group compared to the non-drug use group in patients with a diagnosis of rheumatoid arthritis. The  
560 analysis excluded patients with a prescription history of a TNF blocker and methotrexate.

561 S9 Table. Two by two tables for each of the strata comparing the odds for a diagnosis of Alzheimer's disease or  
562 dementia in rheumatoid arthritis or psoriasis patients who have prescribed a TNF blocker but no methotrexate  
563 prescription history against the general population.

564

565

566

567 **References**

- 568 1. Scheltens P, Blennow K, Breteler MM, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer's disease.  
569 *Lancet*. 2016;388(10043):505-17. doi: 10.1016/S0140-6736(15)01124-1. PubMed PMID: 26921134.
- 570 2. Jack CR, Jr., Bennett DA, Blennow K, Carrillo MC, Dunn B, Haeberlein SB, et al. NIA-AA Research  
571 Framework: Toward a biological definition of Alzheimer's disease. *Alzheimers Dement*. 2018;14(4):535-62. doi:  
572 10.1016/j.jalz.2018.02.018. PubMed PMID: 29653606; PubMed Central PMCID: PMC5958625.
- 573 3. Hansen DV, Hanson JE, Sheng M. Microglia in Alzheimer's disease. *J Cell Biol*. 2018;217(2):459-72.  
574 doi: 10.1083/jcb.201709069. PubMed PMID: 29196460; PubMed Central PMCID: PMC5800817.
- 575 4. Ginhoux F, Greter M, Leboeuf M, Nandi S, See P, Gokhan S, et al. Fate mapping analysis reveals that  
576 adult microglia derive from primitive macrophages. *Science*. 2010;330(6005):841-5. doi:  
577 10.1126/science.1194637. PubMed PMID: 20966214; PubMed Central PMCID: PMC3719181.
- 578 5. Willrich MA, Murray DL, Snyder MR. Tumor necrosis factor inhibitors: clinical utility in autoimmune  
579 diseases. *Transl Res*. 2015;165(2):270-82. doi: 10.1016/j.trsl.2014.09.006. PubMed PMID: 25305470.
- 580 6. Tarkowski E, Andreasen N, Tarkowski A, Blennow K. Intrathecal inflammation precedes development of  
581 Alzheimer's disease. *J Neurol Neurosurg Psychiatry*. 2003;74(9):1200-5. doi: 10.1136/jnnp.74.9.1200. PubMed  
582 PMID: 12933918; PubMed Central PMCID: PMC1738668.
- 583 7. Cheng X, Shen Y, Li R. Targeting TNF: a therapeutic strategy for Alzheimer's disease. *Drug Discov*  
584 *Today*. 2014. doi: 10.1016/j.drudis.2014.06.029. PubMed PMID: 24998784.
- 585 8. Long H, Zhong G, Wang C, Zhang J, Zhang Y, Luo J, et al. TREM2 Attenuates Abeta1-42-Mediated  
586 Neuroinflammation in BV-2 Cells by Downregulating TLR Signaling. *Neurochem Res*. 2019;44(8):1830-9. doi:  
587 10.1007/s11064-019-02817-1. PubMed PMID: 31134514.

- 588 9. McAlpine FE, Tansey MG. Neuroinflammation and tumor necrosis factor signaling in the  
589 pathophysiology of Alzheimer's disease. *J Inflamm Res.* 2008;1:29-39. PubMed PMID: 22096345; PubMed  
590 Central PMCID: PMCPMC3218716.
- 591 10. Liddel SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L, et al. Neurotoxic reactive  
592 astrocytes are induced by activated microglia. *Nature.* 2017;541(7638):481-7. doi: 10.1038/nature21029. PubMed  
593 PMID: 28099414; PubMed Central PMCID: PMCPMC5404890.
- 594 11. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice  
595 expressing human tumour necrosis factor: a predictive genetic model of arthritis. *EMBO J.* 1991;10(13):4025-31.  
596 PubMed PMID: 1721867; PubMed Central PMCID: PMCPMC453150.
- 597 12. Pan W, Kastin AJ. TNFalpha transport across the blood-brain barrier is abolished in receptor knockout  
598 mice. *Exp Neurol.* 2002;174(2):193-200. doi: 10.1006/exnr.2002.7871. PubMed PMID: 11922661.
- 599 13. Chou RC, Kane M, Ghimire S, Gautam S, Gui J. Treatment for Rheumatoid Arthritis and Risk of  
600 Alzheimer's Disease: A Nested Case-Control Analysis. *CNS Drugs.* 2016;30(11):1111-20. doi: 10.1007/s40263-  
601 016-0374-z. PubMed PMID: 27470609; PubMed Central PMCID: PMCPMC5585782.
- 602 14. Kaelber DC, Foster W, Gilder J, Love TE, Jain AK. Patient characteristics associated with venous  
603 thromboembolic events: a cohort study using pooled electronic health record data. *J Am Med Inform Assoc.*  
604 2012;19(6):965-72. doi: 10.1136/amiajnl-2011-000782. PubMed PMID: 22759621; PubMed Central PMCID:  
605 PMCPMC3534456.
- 606 15. Patel VN, Kaelber DC. Using aggregated, de-identified electronic health record data for multivariate  
607 pharmacosurveillance: a case study of azathioprine. *J Biomed Inform.* 2014;52:36-42. doi:  
608 10.1016/j.jbi.2013.10.009. PubMed PMID: 24177317; PubMed Central PMCID: PMCPMC4002671.

- 609 16. Winhusen T, Theobald J, Kaelber DC, Lewis D. Medical complications associated with substance use  
610 disorders in patients with type 2 diabetes and hypertension: electronic health record findings. *Addiction*. 2019.  
611 doi: 10.1111/add.14607. PubMed PMID: 30851217.
- 612 17. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric  
613 protein as a bivalent antagonist of TNF activity. *J Exp Med*. 1991;174(6):1483-9. doi: 10.1084/jem.174.6.1483.  
614 PubMed PMID: 1660525; PubMed Central PMCID: PMC2119031.
- 615 18. Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR. Guiding the selection of human  
616 antibodies from phage display repertoires to a single epitope of an antigen. *Biotechnology (N Y)*. 1994;12(9):899-  
617 903. PubMed PMID: 7521646.
- 618 19. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, et al. Construction and initial  
619 characterization of a mouse-human chimeric anti-TNF antibody. *Mol Immunol*. 1993;30(16):1443-53. PubMed  
620 PMID: 8232330.
- 621 20. Pardridge WM. Blood-brain barrier delivery. *Drug Discov Today*. 2007;12(1-2):54-61. Epub 2007/01/03.  
622 doi: 10.1016/j.drudis.2006.10.013. PubMed PMID: 17198973.
- 623 21. Lindberg C. The Unified Medical Language System (UMLS) of the National Library of Medicine. *J Am*  
624 *Med Rec Assoc*. 1990;61(5):40-2. PubMed PMID: 10104531.
- 625 22. Millar J. The Need for a Global Language - SNOMED CT Introduction. *Stud Health Technol Inform*.  
626 2016;225:683-5. PubMed PMID: 27332304.
- 627 23. Nelson SJ, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: RxNorm at 6  
628 years. *J Am Med Inform Assoc*. 2011;18(4):441-8. doi: 10.1136/amiajnl-2011-000116. PubMed PMID:  
629 21515544; PubMed Central PMCID: PMC2119031.

- 630 24. Huff SM, Rocha RA, McDonald CJ, De Moor GJ, Fiers T, Bidgood WD, Jr., et al. Development of the  
631 Logical Observation Identifier Names and Codes (LOINC) vocabulary. *J Am Med Inform Assoc.* 1998;5(3):276-  
632 92. doi: 10.1136/jamia.1998.0050276. PubMed PMID: 9609498; PubMed Central PMCID: PMC61302.
- 633 25. Kuritz SJ, Landis JR, Koch GG. A general overview of Mantel-Haenszel methods: applications and  
634 recent developments. *Annu Rev Public Health.* 1988;9:123-60. doi: 10.1146/annurev.pu.09.050188.001011.  
635 PubMed PMID: 3288229.
- 636 26. Salloway S, Sperling R, Fox NC, Blennow K, Klunk W, Raskind M, et al. Two phase 3 trials of  
637 bapineuzumab in mild-to-moderate Alzheimer's disease. *N Engl J Med.* 2014;370(4):322-33. doi:  
638 10.1056/NEJMoa1304839. PubMed PMID: 24450891.
- 639 27. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for  
640 mild-to-moderate Alzheimer's disease. *N Engl J Med.* 2014;370(4):311-21. doi: 10.1056/NEJMoa1312889.  
641 PubMed PMID: 24450890.
- 642 28. Alzheimer's A. 2016 Alzheimer's disease facts and figures. *Alzheimers Dement.* 2016;12(4):459-509.  
643 PubMed PMID: 27570871.
- 644 29. Aletaha D, Smolen JS. Diagnosis and Management of Rheumatoid Arthritis: A Review. *JAMA.*  
645 2018;320(13):1360-72. doi: 10.1001/jama.2018.13103. PubMed PMID: 30285183.
- 646 30. Favalli EG, Pregnotato F, Biggioggero M, Becciolini A, Penatti AE, Marchesoni A, et al. Twelve-Year  
647 Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a  
648 Local Registry. *Arthritis Care Res (Hoboken).* 2016;68(4):432-9. doi: 10.1002/acr.22788. PubMed PMID:  
649 26556048.
- 650 31. Papadopoulos CG, Gartzonikas IK, Pappa TK, Markatseli TE, Migkos MP, Voulgari PV, et al. Eight-year  
651 survival study of first-line tumour necrosis factor alpha inhibitors in rheumatoid arthritis: real-world data from a

- 652 university centre registry. *Rheumatol Adv Pract.* 2019;3(1):rkz007. doi: 10.1093/rap/rkz007. PubMed PMID:  
653 31431995; PubMed Central PMCID: PMC6649942.
- 654 32. Heneka MT, Carson MJ, El Khoury J, Landreth GE, Brosseron F, Feinstein DL, et al. Neuroinflammation  
655 in Alzheimer's disease. *Lancet Neurol.* 2015;14(4):388-405. doi: 10.1016/S1474-4422(15)70016-5. PubMed  
656 PMID: 25792098; PubMed Central PMCID: PMC6599703.
- 657 33. Butchart J, Brook L, Hopkins V, Teeling J, Puntener U, Culliford D, et al. Etanercept in Alzheimer  
658 disease: A randomized, placebo-controlled, double-blind, phase 2 trial. *Neurology.* 2015;84(21):2161-8. doi:  
659 10.1212/WNL.0000000000001617. PubMed PMID: 25934853; PubMed Central PMCID: PMC64451045.
- 660 34. Tobinick E, Gross H, Weinberger A, Cohen H. TNF-alpha modulation for treatment of Alzheimer's  
661 disease: a 6-month pilot study. *MedGenMed.* 2006;8(2):25. PubMed PMID: 16926764; PubMed Central PMCID:  
662 PMC61785182.
- 663 35. Tying S, Gottlieb A, Papp K, Gordon K, Leonardi C, Wang A, et al. Etanercept and clinical outcomes,  
664 fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. *Lancet.*  
665 2006;367(9504):29-35. doi: 10.1016/S0140-6736(05)67763-X. PubMed PMID: 16399150.
- 666 36. Peter I, Dubinsky M, Bressman S, Park A, Lu C, Chen N, et al. Anti-Tumor Necrosis Factor Therapy and  
667 Incidence of Parkinson Disease Among Patients With Inflammatory Bowel Disease. *JAMA Neurol.*  
668 2018;75(8):939-46. doi: 10.1001/jamaneurol.2018.0605. PubMed PMID: 29710331; PubMed Central PMCID:  
669 PMC6142934.
- 670 37. Gurney ME, D'Amato EC, Burgin AB. Phosphodiesterase-4 (PDE4) Molecular Pharmacology and  
671 Alzheimer's Disease. *Neurotherapeutics.* 2014. doi: 10.1007/s13311-014-0309-7. PubMed PMID: 25371167.
- 672 38. Chakrabarty P, Li A, Ladd TB, Strickland MR, Koller EJ, Burgess JD, et al. TLR5 decoy receptor as a  
673 novel anti-amyloid therapeutic for Alzheimer's disease. *J Exp Med.* 2018;215(9):2247-64. doi:  
674 10.1084/jem.20180484. PubMed PMID: 30158114; PubMed Central PMCID: PMC6122970.

- 675 39. Probert L. TNF and its receptors in the CNS: The essential, the desirable and the deleterious effects.  
676 Neuroscience. 2015;302:2-22. doi: 10.1016/j.neuroscience.2015.06.038. PubMed PMID: 26117714.
- 677 40. Chung WS, Welsh CA, Barres BA, Stevens B. Do glia drive synaptic and cognitive impairment in  
678 disease? Nat Neurosci. 2015;18(11):1539-45. doi: 10.1038/nn.4142. PubMed PMID: 26505565; PubMed Central  
679 PMCID: PMC4739631.
- 680 41. Salter MW, Stevens B. Microglia emerge as central players in brain disease. Nat Med. 2017;23(9):1018-  
681 27. doi: 10.1038/nm.4397. PubMed PMID: 28886007.
- 682 42. Sims R, van der Lee SJ, Naj AC, Bellenguez C, Badarinarayan N, Jakobsdottir J, et al. Rare coding  
683 variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease.  
684 Nat Genet. 2017;49(9):1373-84. doi: 10.1038/ng.3916. PubMed PMID: 28714976; PubMed Central PMCID:  
685 PMC5669039.
- 686 43. Yeh FL, Hansen DV, Sheng M. TREM2, Microglia, and Neurodegenerative Diseases. Trends Mol Med.  
687 2017;23(6):512-33. doi: 10.1016/j.molmed.2017.03.008. PubMed PMID: 28442216.
- 688 44. Jiang T, Zhang YD, Chen Q, Gao Q, Zhu XC, Zhou JS, et al. TREM2 modifies microglial phenotype and  
689 provides neuroprotection in P301S tau transgenic mice. Neuropharmacology. 2016;105:196-206. doi:  
690 10.1016/j.neuropharm.2016.01.028. PubMed PMID: 26802771.
- 691 45. Bemiller SM, McCray TJ, Allan K, Formica SV, Xu G, Wilson G, et al. TREM2 deficiency exacerbates  
692 tau pathology through dysregulated kinase signaling in a mouse model of tauopathy. Mol Neurodegener.  
693 2017;12(1):74. doi: 10.1186/s13024-017-0216-6. PubMed PMID: 29037207; PubMed Central PMCID:  
694 PMC5644120.
- 695 46. Gorenjak V, Aldasoro Arguinano AA, Dade S, Stathopoulou MG, Vance DR, Masson C, et al. The  
696 polymorphism rs6918289 located in the downstream region of the TREM2 gene is associated with TNF-alpha  
697 levels and IMT-F. Sci Rep. 2018;8(1):7160. doi: 10.1038/s41598-018-25553-y. PubMed PMID: 29740051.

- 698 47. Li P, Zheng Y, Chen X. Drugs for Autoimmune Inflammatory Diseases: From Small Molecule  
699 Compounds to Anti-TNF Biologics. *Front Pharmacol.* 2017;8:460. doi: 10.3389/fphar.2017.00460. PubMed  
700 PMID: 28785220; PubMed Central PMCID: PMC5506195.
- 701 48. Jin SL, Conti M. Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-  
702 activated TNF-alpha responses. *Proc Natl Acad Sci U S A.* 2002;99(11):7628-33. Epub 2002/05/29. doi:  
703 10.1073/pnas.122041599. PubMed PMID: 12032334.
- 704 49. Ghosh M, Garcia-Castillo D, Aguirre V, Golshani R, Atkins CM, Bramlett HM, et al. Proinflammatory  
705 cytokine regulation of cyclic AMP-phosphodiesterase 4 signaling in microglia in vitro and following CNS injury.  
706 *Glia.* 2012. doi: 10.1002/glia.22401. PubMed PMID: 22865690.
- 707 50. Wilson NM, Gurney ME, Dietrich WD, Atkins CM. Therapeutic benefits of phosphodiesterase 4B  
708 inhibition after traumatic brain injury. *PLoS One.* 2017;12(5):e0178013. doi: 10.1371/journal.pone.0178013.  
709 PubMed PMID: 28542295; PubMed Central PMCID: PMC5438188.
- 710 51. Vlad SC, Miller DR, Kowall NW, Felson DT. Protective effects of NSAIDs on the development of  
711 Alzheimer disease. *Neurology.* 2008;70(19):1672-7. doi: 10.1212/01.wnl.0000311269.57716.63. PubMed PMID:  
712 18458226; PubMed Central PMCID: PMC5438188.
- 713 52. Leoutsakos JM, Muthen BO, Breitner JC, Lyketsos CG, Team AR. Effects of non-steroidal anti-  
714 inflammatory drug treatments on cognitive decline vary by phase of pre-clinical Alzheimer disease: findings from  
715 the randomized controlled Alzheimer's Disease Anti-inflammatory Prevention Trial. *Int J Geriatr Psychiatry.*  
716 2012;27(4):364-74. doi: 10.1002/gps.2723. PubMed PMID: 21560159; PubMed Central PMCID:  
717 PMC5438188.
- 718 53. Meyer PF, Tremblay-Mercier J, Leoutsakos J, Madjar C, Lafaille-Maignan ME, Savard M, et al.  
719 INTREPAD: A randomized trial of naproxen to slow progress of presymptomatic Alzheimer disease. *Neurology.*  
720 2019;92(18):e2070-e80. doi: 10.1212/WNL.0000000000007232. PubMed PMID: 30952794; PubMed Central  
721 PMCID: PMC6512884.

- 722 54. Reines SA, Block GA, Morris JC, Liu G, Nessly ML, Lines CR, et al. Rofecoxib: no effect on  
723 Alzheimer's disease in a 1-year, randomized, blinded, controlled study. *Neurology*. 2004;62(1):66-71. doi:  
724 10.1212/wnl.62.1.66. PubMed PMID: 14718699.
- 725 55. Page TH, Turner JJ, Brown AC, Timms EM, Inglis JJ, Brennan FM, et al. Nonsteroidal anti-inflammatory  
726 drugs increase TNF production in rheumatoid synovial membrane cultures and whole blood. *J Immunol*.  
727 2010;185(6):3694-701. doi: 10.4049/jimmunol.1000906. PubMed PMID: 20713883.
- 728 56. Aisen PS, Davis KL, Berg JD, Schafer K, Campbell K, Thomas RG, et al. A randomized controlled trial  
729 of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. *Neurology*. 2000;54(3):588-93.  
730 doi: 10.1212/wnl.54.3.588. PubMed PMID: 10680787.
- 731